Generic Name and Formulations:
Tazarotene 0.1%; foam.
Stiefel Laboratories, Inc.
Indications for FABIOR:
Cleanse and dry affected area. Apply a thin layer to affected areas on face and/or upper trunk once daily in the PM. Women of childbearing potential: begin therapy during normal menses.
Obtain reliable negative pregnancy test within 2 weeks before starting therapy; use effective contraception during therapy. Do not use on broken or eczematous skin. History of local hypersensitivity. Photosensitivity. History of skin cancer. Avoid eyes, lips, mouth, mucous membranes, sun and UV light; use adequate sun protection. Increased irritation in extreme weather. Discontinue if excessive local irritation occurs. Flammable. Nursing mothers: not recommended.
Cumulative irritant effect with concomitant other topical acne therapy; use caution. Avoid use until the effects of strong topical drying agents have subsided. Concomitant oxidizing agents (eg, benzoyl peroxide) may cause tazarotene degradation and reduce efficacy; apply at different times of the day (eg, AM & PM) if combination treatment is needed.
Application site reactions (eg, irritation, dryness, erythema, exfoliation, pain, photosensitivity, pruritus, dermatitis).
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)